28296582|t|Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
28296582|a|Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. Patients and Methods We conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer (T1 to 2a, Gleason score ≤ 6, and prostate-specific antigen [PSA] 10.1 to 20 ng/mL; T2b to 2c, Gleason ≤ 6, and PSA ≤ 20 ng/mL; or T1 to 2, Gleason = 7, and PSA ≤ 20 ng/mL). Patients were allocated to conventional RT of 78 Gy in 39 fractions over 8 weeks or to hypofractionated RT of 60 Gy in 20 fractions over 4 weeks. Androgen deprivation was not permitted with therapy. The primary outcome was biochemical-clinical failure (BCF) defined by any of the following: PSA failure (nadir + 2), hormonal intervention, clinical local or distant failure, or death as a result of prostate cancer. The noninferiority margin was 7.5% (hazard ratio, < 1.32). Results Median follow-up was 6.0 years. One hundred nine of 608 patients in the hypofractionated arm versus 117 of 598 in the standard arm experienced BCF. Most of the events were PSA failures. The 5- year BCF disease-free survival was 85% in both arms (hazard ratio [short v standard], 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected between arms for grade ≥ 3 late genitourinary and GI toxicity. Conclusion The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate cancer.
28296582	0	16	Randomized Trial	T062	C0034656
28296582	22	56	Hypofractionated Radiation Regimen	T061	C1831786
28296582	65	74	Treatment	T061	C0087111
28296582	78	87	Localized	T082	C0392752
28296582	88	103	Prostate Cancer	T191	C0376358
28296582	112	115	Men	T098	C0025266
28296582	121	130	localized	T082	C0392752
28296582	131	146	prostate cancer	T191	C0376358
28296582	157	164	treated	T169	C1522326
28296582	170	191	external radiotherapy	T061	C1517033
28296582	193	195	RT	T061	C1522449
28296582	209	214	weeks	T079	C0439230
28296582	216	235	Hypofractionated RT	T061	C1831786
28296582	252	264	shorter time	T079	C0040223
28296582	270	282	larger doses	T081	C0178602
28296582	287	296	treatment	T061	C0087111
28296582	302	310	standard	T080	C1442989
28296582	311	313	RT	T061	C1522449
28296582	336	353	hypofractionation	T061	C4042795
28296582	361	387	conventional fractionation	T061	C0524811
28296582	391	398	similar	T080	C2348205
28296582	402	410	efficacy	T080	C1280519
28296582	419	428	increased	T081	C0205217
28296582	429	437	toxicity	T080	C0040539
28296582	439	447	Patients	T101	C0030705
28296582	475	518	multicenter randomized noninferiority trial	T062	C0206012
28296582	522	539	intermediate-risk	T033	C3640764
28296582	540	555	prostate cancer	T191	C0376358
28296582	567	580	Gleason score	T033	C3203027
28296582	590	615	prostate-specific antigen	T116,T126,T129	C0138741
28296582	617	620	PSA	T116,T126,T129	C0138741
28296582	651	658	Gleason	T033	C3203027
28296582	668	671	PSA	T116,T126,T129	C0138741
28296582	696	703	Gleason	T033	C3203027
28296582	713	716	PSA	T116,T126,T129	C0138741
28296582	730	738	Patients	T101	C0030705
28296582	744	753	allocated	T169	C0205245
28296582	757	772	conventional RT	T061	C1522449
28296582	788	797	fractions	T081	C1264633
28296582	805	810	weeks	T079	C0439230
28296582	817	836	hypofractionated RT	T061	C1831786
28296582	852	861	fractions	T081	C1264633
28296582	869	874	weeks	T079	C0439230
28296582	876	896	Androgen deprivation	T061	C1515985
28296582	920	927	therapy	T061	C0087111
28296582	933	948	primary outcome	T080	C0085415
28296582	953	981	biochemical-clinical failure	T033	C3640841
28296582	983	986	BCF	T033	C3640841
28296582	1021	1024	PSA	T116,T126,T129	C0138741
28296582	1025	1032	failure	T169	C0231174
28296582	1046	1054	hormonal	T080	C0458083
28296582	1055	1067	intervention	T080	C0205556
28296582	1069	1102	clinical local or distant failure	T033	C3640841
28296582	1107	1112	death	T040	C0011065
28296582	1118	1124	result	T169	C1274040
28296582	1128	1143	prostate cancer	T191	C0376358
28296582	1149	1170	noninferiority margin	T081	C0392762
28296582	1181	1193	hazard ratio	T081	C2985465
28296582	1212	1228	Median follow-up	T058	C1522577
28296582	1237	1242	years	T079	C0439234
28296582	1244	1260	One hundred nine	T081	C0392762
28296582	1268	1276	patients	T101	C0030705
28296582	1284	1304	hypofractionated arm	T061	C1831786
28296582	1330	1342	standard arm	T061	C1522449
28296582	1355	1358	BCF	T033	C3640841
28296582	1372	1378	events	T051	C0441471
28296582	1384	1387	PSA	T116,T126,T129	C0138741
28296582	1388	1396	failures	T169	C0231174
28296582	1405	1409	year	T079	C0439234
28296582	1410	1413	BCF	T033	C3640841
28296582	1414	1435	disease-free survival	T081	C0242793
28296582	1458	1470	hazard ratio	T081	C2985465
28296582	1501	1503	CI	T081	C0009667
28296582	1519	1522	Ten	T081	C0205456
28296582	1523	1529	deaths	T040	C0011065
28296582	1535	1541	result	T169	C1274040
28296582	1545	1560	prostate cancer	T191	C0376358
28296582	1577	1586	short arm	T061	C1831786
28296582	1601	1613	standard arm	T061	C1522449
28296582	1615	1629	No significant	T033	C1273937
28296582	1630	1641	differences	T080	C1705242
28296582	1647	1655	detected	T033	C0442726
28296582	1688	1701	genitourinary	T029	C3887515
28296582	1706	1708	GI	T082	C0521362
28296582	1709	1717	toxicity	T080	C0040539
28296582	1734	1761	hypofractionated RT regimen	T061	C1831786
28296582	1775	1780	trial	T062	C0008976
28296582	1801	1816	conventional RT	T061	C1522449
28296582	1829	1844	associated with	T080	C0332281
28296582	1845	1854	increased	T081	C0205217
28296582	1860	1868	toxicity	T080	C0040539
28296582	1870	1889	Hypofractionated RT	T061	C1831786
28296582	1898	1908	convenient	T080	C3831015
28296582	1913	1921	patients	T101	C0030705
28296582	1951	1968	intermediate-risk	T033	C3640764
28296582	1969	1984	prostate cancer	T191	C0376358